Search
logo
Search
The article is in preview mode

Dyslipidemia as elevated cholesterol affects your health

Homepage Articles Dyslipidemia as elevated cholesterol affects your health

Dyslipidemia as elevated cholesterol affects your health

Drygas et al., 2015). Elevated cholesterol or an abnormal lipid profile are problems that more and more people are struggling with. Dyslipidemia, or disorders in the concentration of fatty substances in the blood, can occur independently or accompany chronic diseases, so it is worthwhile to familiarize yourself with the basic concepts associated with this disease, its consequences and methods of treatment. According to epidemiological studies, they can affect up to about 60% of Poles aged 2074 years (W.

Table of Contents

1. Dyslipidemia is a lipid economy

Their task is to transport fat to the body's tissues, where it can be stored, used as an energy source, or as a building block for other components such as hormones and bile acids to function properly. One of the groups that are important in managing fat resources are lipoproteins, which are molecules that combine fat and protein. To understand the problem of dyslipidemia, we must first look at the principles of fat management in the body.

2. Types of lipoproteins and their function in the body (F. Mach et al. 2020)

The presence of LDL, VLDL, and IDL in the arterial walls also causes complex reactions in which the triglycerides, or fatty compounds, are deposited in them. When increased, it can cause a breakdown and complete shutdown of the vessel's light, which prevents blood flow and the supply of essential nutrients to the organs. In the lipid economy, triglycers also play an important role, i.e. the chemical compounds composed of glycerol and fatty acids in the blood.

3. Dyslipidemia definition and cause

In the International Classification of Diseases (ICD-10), dyslipidemia may also occur in the course of other diseases (e.g. thyroid disease, Cushing's disease, but type 2 diabetes and its associated insulin resistance), or as a result of taking certain medicinal products (as in familial hypercholesterolemia, which is passed down from generation to generation).

4. Dyslipidemia is a diagnosis

However, it is emphasized that if it is low, it increases the risk of cardiovascular incident (including heart attack) and death in patients with coronary disease (F. To diagnose lipid-related disorders, blood is collected from the patient, which is then called lipid profile, i.e. total cholesterol (TC), HDL (HDL-C), high-density lipoprotein fraction cholesterol (HDL-C) and LDL (LDL-L), and LDL-L, Triglycine (TG, TG), respectively. If the following dosages are established for men (1, 400 mg/LDL) and for women (1, 500 mg/MLDL), it is considered to be a new dosage of 100 mg/mLDL (in Europe) for women (150 mmLDL and 4 mg/C) (the following dosage values for women) are:

5. Dyslipidemia Symptoms and health consequences

Their consequences may be: increased fatigue, reduced resistance to physical exertion, problems with movement (lower extremity thrombosis), severe abdominal pain (changes within the blood vessels of the intestines) or kidney damage. The most serious consequences include a stroke, a condition in which blood does not reach the organ, which causes its lack of oxygen and can lead to death causes heart, brain or intestinal dysfunction, among others. Due to such severe surgery and the absence of early symptoms of abnormalities, it is difficult to maintain regular or non-regular lipid functioning, and in the case of an emergency procedure, it may lead to the death of the organ itself, as well as to a permanent liver disease (such as cardiovascular disease, which usually leads to death, which is not caused by blood disorders).

6. Dyslipidemia is treated

Among the medicines used in dyslipidemia are: a group of statins that inhibit the production of cholesterol in the liver, cholesterol absorption inhibitors that limit the amount of cholesterol absorbed from food in the intestine, causing the ingredient to be excreted; medicines that bind bile acids combine with bile acid and reduce blood circulating bile, resulting in an increase in cholesterol production that is already available in the body. Inhibitors of prophylactic lipid synthesis (PCOS 9), as well as other anti-inflammatory compounds used in pharmaceutical formulations such as PCOS 9 and PCOS 9, which have been shown to have a positive effect on the use of lipid- and cholesterol-lowering drugs in patients with at least 30 years of age, and in patients who have been diagnosed with lipid deficiency in the blood, have shown to be able to reduce their body weight in a number of lifetimes.
Source

Catapano A.L. et al., Wytyczne ESC/EAS dotyczące leczenia zaburzeń lipidowych w 2016 roku, „Kardiologia Polska” 2016, 74(11), 1234–1318.
Drygas W. et al., Wieloośrodkowe Ogólnopolskie Badanie Stanu Zdrowia Ludności – WOBASZ, Epidemiologia i prewencja chorób układu krążenia, pod red. Kopcia G. et al., Kraków 2015, 41–56.
Gajewski P., Interna Szczeklika – mały podręcznik 2016/2017, Kraków 2016, 140–144.
Kliniczny zarys chorób wewnętrznych. Podręcznik dla studentów dietetyki, pod red. Cymerysa M. et al., Poznań 2013, 214.
Mach F. et al., Wytyczne ESC/EAS dotyczące postępowania w dyslipidemiach: jak dzięki leczeniu zaburzeń lipidowych obniżyć ryzyko sercowo-naczyniowe (2019), „Zeszyty Edukacyjne. Kardiologia Polska” 2020, 3, 23–49.